摘要
背景与目的肺癌化疗疗效与肿瘤的基因表达有关,本研究拟探讨ERCC1、RRM1表达与非小细胞肺癌术后吉西他滨联合顺铂(GP)辅助化疗预后的关系。方法随访57例临床Ⅱ-Ⅳ期接受手术治疗的非小细胞肺癌患者,其中术后接受2周期以上化疗者39例(化疗组),未化疗者18例(未化疗组)。采用免疫组化法检测ERCC1、RRM1表达,Cox回归分析筛选影响预后的独立危险因子,Kaplan-Meier生存曲线分析比较各组患者的中位生存时间。结果Cox回归分析显示手术彻底程度、术后辅助化疗与否、ERCC1表达水平为影响术后生存时间的独立危险因子。ERCC1低表达组中化疗组和未化疗组中位生存期分别为23个月和21个月(P=0.088),ERCC1高表达组中化疗组和未化疗组中位生存期分别为42个月和12个月(P=0.018)。RRM1低表达组中化疗组和未化疗组中位生存期分别为42个月和22个月(P=0.010),RRM1高表达组中化疗组和未化疗组中位生存期分别为28个月和21个月(P=0.092)。结论ERCC1高表达、RRM1低表达的非小细胞肺癌患者更能从术后吉西他滨联合顺铂的化疗中受益。
Background and objective It has been proved that the chemotherapy respouse was related to the expression levels of tumor genes in lung cancer. The aim of this study was to explor the relationship of ERCC1, RRM1 expression and the benefits from postoperative cisplatin combined with gemcitabine （GP） chemotherapy in patients with non-small cell lung cancer （NSCLC）. Methods All 57 postoperative patients with stage Ⅱ -Ⅳ NSCLC were entered into the study, and 39 cases of patients were at least received 2 cycles of cisplatin eombind with gemcitabine chemotherapy, 18 cases with no chemotherapy. Immunohistochemistry was performed in paraffin-embedded tumor specimens to investigate ERCC1, RRM1 expression. Cox proportional regression analysis was used to screen independent prognostic risk factors for survival. Comparisons of the median survival time among groups were based on Kaplan-Meier analysis. Results Cox regression analyses showed that the extent of tumor resection, chemotherapy after surgical resection and expressions of ERCC1 were independent prognostic factors. In the group of high expression of ERCC1, the median survival time of postoperative chemotherapy patients and control were 42 and 12 months respectively （P=0.018）. In the group with low expression of ERCC1, the median survival time of postoperative chemotherapy patients and control were 23 and 21 months respectively （P=0.088）. However, In the group of high expression of RRM1, the median survival time of postoperative chemotherapy patients and control were 28 and 21 months respectively （P=0.092）. In the group with low expression of RRM1, the median survival time of postoperative chemotherapy patients and control were 42 and 22 months respectively （P=0.010）. Conclusion The NSCLC patients with high expression of ERCC1 and low expression of RRM1 get more probablely benefits from postoperative eisplatin combine gemcitabine chemotherapy.
出处
《中国肺癌杂志》
CAS
2009年第5期403-407,共5页
Chinese Journal of Lung Cancer
关键词
肺肿瘤
吉西他滨/顺铂
ERCC1
RRM1
Lung neoplasms
Cisplatin/gemeitabine
Excision repair cross-complementing gene 1
Ribonucleotide reductase subunit 1
